Merck (MRK) Change in Cash (2009 - 2026)
Merck (MRK) reported Change in Cash of -$9.3 billion for Q1 2026, down 102.62% year-over-year from $355.1 billion in Q1 2025, and down 160.28% quarter-over-quarter from -$3.6 billion in Q4 2025.
Merck (MRK) Change in Cash (2009 - 2026) Analysis & Trends
Merck (MRK) has 18 years of Change in Cash data on file, last reported at -$9.3 billion in Q1 2026.
- Change in Cash for Q1 2026 came in at -$9.3 billion, down 102.62% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.3 billion (down 208.92% YoY), and the FY2025 annual result was $1.4 billion, down 78.59% from the prior year.
- Change in Cash slipped to -$9.3 billion in Q1 2026 per MRK's latest filing, from -$3.6 billion in the prior quarter.
- Over five years, Change in Cash peaked at $10.2 billion in Q3 2025 and troughed at -$9.3 billion in Q1 2026.
- A 5-year average of -$162.9 million and a median of -$659.0 million in 2025 frame the typical range for Change in Cash.
- The sharpest annual moves came in 2023 and 2024: Change in Cash sank 768.23% in 2023, then surged 239.96% in 2024.
- A 5-year view of Change in Cash shows it stood at $1.5 billion in 2022, then sank by 217.8% to -$1.8 billion in 2023, then increased by 22.16% to -$1.4 billion in 2024, then sank by 160.58% to -$3.6 billion in 2025, then sank by 160.28% to -$9.3 billion in 2026.
- Business Quant data shows MRK's Change in Cash at -$9.3 billion in Q1 2026, -$3.6 billion in Q4 2025, and $10.2 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -71.45 Mn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | -1.99 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 1.98 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 4.16 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -9.29 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 2.91 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 65.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 563.00 Mn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -635.00 Mn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.29 Bn |
| Dec 31, 2025 | -3.57 Bn |
| Sep 30, 2025 | 10.19 Bn |
| Jun 30, 2025 | -659.00 Mn |
| Mar 31, 2025 | -4.59 Bn |
| Dec 31, 2024 | -1.37 Bn |
| Sep 30, 2024 | 3.32 Bn |
| Jun 30, 2024 | 5.70 Bn |
| Mar 31, 2024 | -1.24 Bn |
| Dec 31, 2023 | -1.76 Bn |
| Sep 30, 2023 | 2.96 Bn |
| Jun 30, 2023 | -4.07 Bn |
| Mar 31, 2023 | -2.99 Bn |
| Dec 31, 2022 | 1.49 Bn |
| Sep 30, 2022 | 1.53 Bn |
| Jun 30, 2022 | 1.14 Bn |
| Mar 31, 2022 | 447.00 Mn |
| Dec 31, 2021 | -1.88 Bn |
| Sep 30, 2021 | 1.42 Bn |
| Jun 30, 2021 | 1.62 Bn |